Targovax plans checkpoint combo trial after posting early data on oncolytic virus

FierceBiotech | January 22, 2020

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the lungs. That belief is underpinned by preclinical evidence that ONCOS-102 directly kills cancer cells and triggers an innate immune response.

Spotlight

The microscopic green plants cleaned up the earth's atmosphere millions of years ago and scientists hope they can do it now by helping remove greenhouse gases and create new oil reserves.

Spotlight

The microscopic green plants cleaned up the earth's atmosphere millions of years ago and scientists hope they can do it now by helping remove greenhouse gases and create new oil reserves.

Related News

Bio-K Plus International is expanding its portfolio of probiotic products and is launching a new line of functional beverages infused with probiotics

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and modern lifestyle of today's consumer, always looking for innovative ways to stay healthy. Bio-K Plus offers a dose of probiotics in the form of fun, delightful and balanced functional beverages. This announcement is the result of more than two years of research and development carried out by Bio-K Plus' experienced team that has developed the best line of functional beverages infused with probiotic bacteria. This project was led by Martin Croteau, Chief Commercial Officer, and was driven by the need to democratize probiotics, making them more accessible for all, and broaden their use to support global health in a more holistic manner.

Read More

MEDICAL

AlgaEnergy Agreements with Laboratoire M2 for Distribution and Product Development

AlgaEnergy | January 14, 2021

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for the world's producers. Laboratoire M2's THYMOX® items, gotten from the antimicrobial intensity of thyme oil and other regular oils, are utilized in harvest and indoor farming, just as in turf and nursery markets. Under the arrangements, AlgaEnergy will acquire restrictive worldwide rights to disperse the THYMOX crop insurance product offering through AlgaEnergy's specialty units in key rural business sectors in Europe, the Americas, Africa and Asia-Pacific. The two organizations likewise marked a permit and collective item advancement understanding under which their logical groups will together attempt to make new, value-added biocontrol products.

Read More

MEDTECH

Seegene Develops World's First COVID-19 Diagnostic Variant Test Capable of Identifying Multiple Mutant Variations

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-19, yet can likewise recognize major genetic variations that appear to have originated from the UK, South Africa just as different districts including Japan and Brazil. Besides, it can pre-screen a suspicious new variant, giving understanding on extra variations, likewise a critical component of Seegene technology. Seegene's new item incorporates in any event ten of its proprietary technologies, including multiplex real-time PCR technique for mTOCE™, which is the forefront technology that solitary Seegene can use. This imaginative technology permits the test to distinguish an objective explicit spot where mutation occurs, empowering exact detection and separation of the Covid just as its transformed versions with a single tube of reagent.

Read More